Athena Athena

X
[{"orgOrder":0,"company":"Persica Pharmaceuticals","sponsor":"Micron Research Ltd","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Persica Pharmaceuticals has Completed the First Stage of Its Clinical Trial on Unique Injectable PP353, To Treat Chronic Lower Back Pain","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I"}]

Find Clinical Drug Pipeline Developments & Deals by Persica Pharmaceuticals

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            PP353 is a sustained release formulation of an antibiotic to treat the chronic disc infection, which is designed for intradiscal injection under image guidance.

            Lead Product(s): PP353

            Therapeutic Area: Musculoskeletal Product Name: PP353

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Micron Research Ltd

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 19, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY